- Home
- THRD vs PACB Comparison
THRD vs PACB Comparison
Compare THRD & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- PACB
- Stock Information
- Founded
- THRD 2019
- PACB 2000
- Country
- THRD United States
- PACB United States
- Employees
- THRD N/A
- PACB N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- THRD Health Care
- PACB Industrials
- Exchange
- THRD Nasdaq
- PACB Nasdaq
- Market Cap
- THRD 513.2M
- PACB 452.1M
- IPO Year
- THRD 2022
- PACB 2010
- Fundamental
- Price
- THRD $11.45
- PACB $1.77
- Analyst Decision
- THRD Strong Buy
- PACB Buy
- Analyst Count
- THRD 3
- PACB 15
- Target Price
- THRD $20.33
- PACB $2.92
- AVG Volume (30 Days)
- THRD 218.2K
- PACB 12.4M
- Earning Date
- THRD 11-07-2024
- PACB 11-07-2024
- Dividend Yield
- THRD N/A
- PACB N/A
- EPS Growth
- THRD N/A
- PACB N/A
- EPS
- THRD N/A
- PACB N/A
- Revenue
- THRD N/A
- PACB $173,147,000.00
- Revenue This Year
- THRD N/A
- PACB N/A
- Revenue Next Year
- THRD N/A
- PACB $25.88
- P/E Ratio
- THRD N/A
- PACB N/A
- Revenue Growth
- THRD N/A
- PACB 2.14
- 52 Week Low
- THRD $7.08
- PACB $1.16
- 52 Week High
- THRD $16.94
- PACB $10.65
- Technical
- Relative Strength Index (RSI)
- THRD 40.06
- PACB 43.55
- Support Level
- THRD $10.10
- PACB $1.49
- Resistance Level
- THRD $12.49
- PACB $2.66
- Average True Range (ATR)
- THRD 1.30
- PACB 0.30
- MACD
- THRD -0.32
- PACB -0.08
- Stochastic Oscillator
- THRD 25.00
- PACB 22.76
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.